H.R. 8339 · 119th Congress · Health

Drug Origin Transparency Act of 2026

In committee613 words Introduced Apr 16, 2026 · Latest action Apr 16, 2026

How far it has goneStage 2 of 6
  1. IntroducedApr 16, 2026 Done
  2. CommitteeReferred to Energy and Commerce Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

2 organizations, more than 78% of House bills · 3 filings · Q2 2026–Q3 2026

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Vizient Inc 2 of 2 quarters
    “…Continued monitoring and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339). Hospital Data and Analytics - Provided education on the types of clinical, operational, financial and quality data hospitals collect and monitor to improve patient care, including how providers use data to assess and…”

    $940K lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Association for Accessible Medicines 1 of 2 quarters
    “…H.R.8339: Drug Origin Transparency Act of 2026.”

    $2.5M lobbying spend in 2026 to date, all issuesQ2 2026 filing

Organizations that named H.R. 8339 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Apr 16, 2026Referred to the House Committee on Energy and Commerce.
  2. Apr 16, 2026Introduced in House